The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations

• Published in: British journal of cancer Vol. 127; no. 1; pp. 84 - 91
• Main Authors: Tomiczek-Szwiec, Joanna, Szwiec, Marek, Falco, Michal, Cybulski, Cezary, Wokolorczyk, Dominika, Jakubowska, Anna, Gronwald, Jacek, Stawicka, Malgorzata, Godlewski, Dariusz, Kilar, Ewa, Marczyk, Elzbieta, Siołek, Monika, Wiśniowski, Rafal, Haus, Olga, Sibilski, Robert, Bodnar, Lubomir, Sun, Ping, Narod, Steven A., Lubinski, Jan, Huzarski, Tomasz
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.07.2022; Nature Publishing Group
• Subjects: 631/67/1347; 631/67/68; Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - surgery; Cancer Research; Cancer therapies; Checkpoint Kinase 2 - genetics; Chemotherapy; Death; Drug Resistance; Epidemiology; Female; Genetic Predisposition to Disease; Humans; Medical records; Molecular Medicine; Mutation; Oncology; Oophorectomy; Ovariectomy; Patients; Proportional Hazards Models; Radiation therapy; Risk Factors; Survival
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/s41416-022-01770-1

Background To estimate the impact of oophorectomy and other treatments on the survival of breast cancer patients with a CHEK2 mutation. Methods Women with Stage I–III breast cancer who were treated at 17 hospitals in Poland were tested for four founder mutations in the CHEK2 gene. 974 women (10%) were positive for a CHEK2 mutation. Control patients without a CHEK2 mutation were selected from a database of patients treated over the same time period. Information on treatments received and distant recurrences were retrieved from medical records. Treatments included chemotherapy, hormonal therapy (tamoxifen) and radiation therapy. Oophorectomies were performed for the treatment of breast cancer or for benign conditions. Dates of death were obtained from the Polish Vital Statistics Registry. Causes of death were determined by medical record review. Predictors of survival were determined using the Cox proportional hazards model. Results In all, 839 patients with a CHEK2 mutation were matched to 839 patients without a mutation. The mean follow-up was 12.0 years. The 15-year survival for CHEK2 carriers was 76.6% and the 15-year survival for non-carrier control patients was 78.8% (adjusted HR = 1.06; 95% CI: 0.84–1.34; P  = 0.61). Among CHEK2 carriers, the 15-year survival for women who had an oophorectomy was 86.3% and for women who did not have an oophorectomy was 72.1% (adjusted HR = 0.59; 95% CI: 0.38–0.90; P  = 0.02). Among controls, the 15-year survival for patients who had an oophorectomy was 84.5% and for women who did not have an oophorectomy was 77.6% (adjusted HR = 1.03; 95% CI: 0.66–1.61; P  = 0.90). Conclusion Among women with breast cancer and a CHEK2 mutation, oophorectomy is associated with a reduced risk of death from breast cancer.